<?xml version='1.0' encoding='utf-8'?>
<document id="29688628"><sentence text="Pharmacokinetics, Pharmacodynamics, and Tolerability of Concomitant Administration of Verinurad and Febuxostat in Healthy Male Volunteers."><entity charOffset="100-110" id="DDI-PubMed.29688628.s1.e0" text="Febuxostat" /></sentence><sentence text="Verinurad (RDEA3170) is a selective uric acid reabsorption inhibitor in development for treatment of gout and asymptomatic hyperuricemia"><entity charOffset="36-45" id="DDI-PubMed.29688628.s2.e0" text="uric acid" /></sentence><sentence text=" This phase 1, single-blind, multiple-dose, drug-drug interaction study evaluated the pharmacokinetics (PK), pharmacodynamics, and safety/tolerability of verinurad in combination with febuxostat in healthy male volunteers"><entity charOffset="184-194" id="DDI-PubMed.29688628.s3.e0" text="febuxostat" /></sentence><sentence text=" Twenty-three subjects were randomized and received once-daily doses of verinurad (or placebo) or febuxostat alone (days 1-7 and days 15-21), or verinurad + febuxostat on days 8-14" /><sentence text=" For combinations, subjects received verinurad 10 mg + febuxostat 40 mg or verinurad 2" /><sentence text="5 mg + febuxostat 80 mg" /><sentence text=" Plasma/serum and urine samples were analyzed for verinurad, febuxostat, and uric acid"><entity charOffset="61-71" id="DDI-PubMed.29688628.s7.e0" text="febuxostat" /><entity charOffset="77-86" id="DDI-PubMed.29688628.s7.e1" text="uric acid" /><pair ddi="false" e1="DDI-PubMed.29688628.s7.e0" e2="DDI-PubMed.29688628.s7.e0" /><pair ddi="false" e1="DDI-PubMed.29688628.s7.e0" e2="DDI-PubMed.29688628.s7.e1" /></sentence><sentence text=" Safety was assessed by adverse events and laboratory tests" /><sentence text=" Febuxostat 40 mg had no effect on plasma exposure of verinurad 10 mg, whereas febuxostat 80 mg increased the maximum observed plasma concentration and the area under the plasma concentration-time curve of verinurad 2"><entity charOffset="1-11" id="DDI-PubMed.29688628.s9.e0" text="Febuxostat" /></sentence><sentence text="5 mg by 25% and 33%, respectively" /><sentence text=" Verinurad had no effect on febuxostat PK" /><sentence text=" Maximal reduction in serum urate was 76% with verinurad 10 mg + febuxostat 40 mg versus verinurad 10 mg (56%) or febuxostat 40 mg (49%) alone and was 67% with verinurad 2"><entity charOffset="28-33" id="DDI-PubMed.29688628.s12.e0" text="urate" /><entity charOffset="114-124" id="DDI-PubMed.29688628.s12.e1" text="febuxostat" /><pair ddi="false" e1="DDI-PubMed.29688628.s12.e0" e2="DDI-PubMed.29688628.s12.e0" /><pair ddi="false" e1="DDI-PubMed.29688628.s12.e0" e2="DDI-PubMed.29688628.s12.e1" /></sentence><sentence text="5 mg + febuxostat 80 mg versus verinurad 2" /><sentence text="5 mg (38%) or febuxostat 80 mg (57%) alone" /><sentence text=" Verinurad increased, whereas febuxostat decreased, 24-hour fractional excretion and renal clearance of uric acid"><entity charOffset="104-113" id="DDI-PubMed.29688628.s15.e0" text="uric acid" /></sentence><sentence text=" There was no clinically significant drug-drug interaction between verinurad and febuxostat PK" /><sentence text=" The combination resulted in greater reductions of serum urate than either drug alone and was well tolerated at the studied doses"><entity charOffset="57-65" id="DDI-PubMed.29688628.s17.e0" text="urate" /></sentence><sentence text="" /></document>